Message from the Program Co-Chair
Mobilizing medical insight, discovery and invention to help patients is a team effort. Patients and their families expect that we will work collaboratively and use our collective skills to improve health – as efficiently and quickly as possible. No doubt, collaboration is a skill and a challenge. Honing that skill and exploring the challenge requires conversation and expression. The DIA 2015 51st Annual Meeting gathering in Washington, DC, is the perfect place to pursue our shared mission to improve health and well-being, and to learn how to be great partners in drug development from each other.
To that end, I am honored to serve as Program Co-Chair of the DIA 2015 51st Annual Meeting, alongside Dr. Christopher Austin, Director of the National Center for Advancing Translational Sciences (NCATS). Dr. Austin and I join together at a time when collaboration throughout the research and health care communities can accelerate the generation and implementation of innovations for patients.
The DIA 2015 51st Annual Meeting gives us a special place and time to connect with people and organizations with cutting-edge ideas to accelerate development of new therapies and explore and exchange ways to enhance health and well-being – from engaging with patients to applying information technologies that shift how we work with each other.
By participating in the insightful and stimulating sessions offered this year, you will have unprecedented access to thought leaders from global and regional regulatory agencies and constituents in the pharmaceutical, biotechnology, and medical products industry in a collegial environment where improving health is the common goal.
The sessions are many and the topics thought provoking and informative. They include:
Disruptive Forces in Health Care Innovation: Where Are They Leading Us?
Breakthrough Medicines or Affordable Health Care: Do We Have to Choose?
Operationalizing the Pragmatic Clinical Trial: The Role of PCORI and the Pharmaceutical Industry
International Regulatory Convergence: Collaboration, Cooperation and Global Governance
The Future of Clinical Trial Data Sharing
An Insider’s View of Cooperation Between the EMA and CDER/FDA: Question Time
The DIA Annual Meeting is a forum – a community – for you to further build the skills necessary to pioneer new patient therapies in the 21st Century. Together with my DIA colleagues, I hope you will join us next month in Washington, DC. I look forward to meeting you.
Michael Rosenblatt, MD
Executive Vice President and Chief Medical Officer
Merck & Co. Inc.
DIA 2015 51st Annual Meeting Program Co-Chair